BeStock  
Stocks › Biotechnology › PHAT

Phathom Pharmaceuticals PHAT

US equityMarket cap rank #3686Biotechnology
$4.66 −$0.42 (-8.27%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $4.66 0.00%
Open$4.93
Prev close$5.08
Day range$4.62 – $5.15
Volume1.33M
Market cap$378.82M
P/E (TTM)–
Dividend yield–

PHAT Stock News

Headlines matching Phathom Pharmaceuticals or the PHAT ticker, most recent first.

  • Leerink Partners Initiates Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Announces Target Price $10Market news · 9 Sep 2026 · Direct mention
  • H.C. Wainwright Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)TipRanks · 22 Sep 2026 · Direct mention
  • H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26Market news · 22 Sep 2026 · Direct mention
  • Barclays Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $14 NegativeMarket news · 17 Aug 2026 · Direct mention
  • Raymond James Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $21 NegativeMarket news · 31 Jul 2026 · Direct mention
  • Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $20Market news · 31 Jul 2026 · Direct mention
  • Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $22 NegativeMarket news · 31 Jul 2026 · Direct mention
  • Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $22 NegativeMarket news · 31 Jul 2026 · Direct mention
  • Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $0.00 per Share, Vs. FactSet Est of $-0.19MT Newswires · 30 Jul 2026 · Direct mention
  • Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28Market news · 22 Jul 2026 · Direct mention
  • Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $25Market news · 22 Jul 2026 · Direct mention
  • Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy RatingMarket news · 14 Jul 2026 · Direct mention
  • Barclays Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $18Market news · 15 May 2026 · Direct mention
  • A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $25 to $28Market news · 1 May 2026 · Direct mention
  • Barclays Upgrades Phathom Pharmaceuticals(PHAT.US) to Buy Rating, Raises Target Price to $18 PositiveMarket news · 27 Mar 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on PHAT.

Sign in to join the discussion.

Scroll to Top